Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Hurdles to CAR-T therapy for MDS & AML: T-cell fitness & lack of a uniform target antigen

David Sallman, MD, Moffitt Cancer Center, Tampa, FL, outlines the current challenges in bringing CAR-T therapies to myeloid malignancies such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Dr Sallman highlights two concerns; the lack of a uniform target antigen, and poor T-cell fitness and function, the former he suggests could be overcome by developing cellular therapies targeting more than one antigen. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Takeda: Consultancy; Shattuck Labs: Membership on an entity’s Board of Directors or advisory committees; Kite: Membership on an entity’s Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Incyte: Speakers Bureau; Syndax: Membership on an entity’s Board of Directors or advisory committees; Magenta: Consultancy; Intellia: Membership on an entity’s Board of Directors or advisory committees; BMS: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Aprea: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Agios: Membership on an entity’s Board of Directors or advisory committees; AbbVie: Membership on an entity’s Board of Directors or advisory committees; Syntrix Pharmaceuticals: Research Funding; Lixte: Patents & Royalties: LB-100; Nemucore: Membership on an entity’s Board of Directors or advisory committees